Specifically, the drug has been granted a Category 2a designation in combination with lenalidomide as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
NCCN is a network of 30 leading cancer centers devoted to patient care, research and education. Its guidelines aim to aid the decision-making process of individuals involved in cancer care.
The drug has been developed under a clinical collaboration between MorphoSys and Incyte and is currently approved in the US in combination with lenalidomide for the treatment of adults with relapsed or refractory DLBCL.
Price: 31.97, Change: -0.63, Percent Change: -1.93
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|